Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, Conference Calls/ Webcasts

Option Care Health to Participate in the J.P. Morgan Healthcare Conference


BANNOCKBURN, Ill., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Option Care Health Inc. ("Option Care Health") (NASDAQ: OPCH), the nation's largest independent national provider of home and alternate site infusion services, will participate in the 42nd Annual J.P. Morgan Healthcare Conference, being held in San Francisco, on Tuesday, January 9, 2024, including a presentation at 3:00pm PT. The webcast and related presentation materials will be available online at https://investors.optioncarehealth.com.

About Option Care Health

Option Care Health is the nation's largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.

For Investor Inquiries:
Mike Shapiro, Chief Financial Officer
Option Care Health
312.940.2538
[email protected]



These press releases may also interest you

11 mai 2024
Fast-Growing Prior Authorization Software Company Announces Addition of Chief Revenue Officer
eBlu Solutions, a leading provider of innovative technology solutions for the specialty healthcare industry, is pleased to announce the addition of Doug Lawrence to the Executive Leadership team in the role of Chief Revenue Officer. "We're not just...

11 mai 2024
NUVISTA Mental Health Joins As Gold Sponsors For 2024 First Responders Mental Health Conference
NUVISTA Mental Health proudly announces its participation as a Gold Sponsor for the 2024 Ontario First...

11 mai 2024
Cardurion Pharmaceuticals Presents Positive Clinical Results from CARDINAL?HF Phase 2a Clinical Trial of PDE9 Inhibitor in Patients With Heart Failure
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the presentation of positive clinical data from CARDINAL?HF,...

11 mai 2024
KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value
Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSH&RC) joined the Gulf Creatives Conference (GCC) at Harvard 2024. The event, GCC at Harvard, is organized by The Diwan, an organization run by graduate students at...

11 mai 2024
Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel Self-Replicating RNA at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use across a range of infectious disease, oncology,...

11 mai 2024
Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention
Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place in...

More news about Health...


News published on and distributed by: